Related Experiment Videos
Clinical proteomics: translating benchside promise into bedside reality.
Emanuel F Petricoin1, Kathryn C Zoon, Elise C Kohn
1FDA-NCI Clinical Proteomics Program, Division of Therapeutic Proteins, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA. petricoin@cber.fda.gov
Nature Reviews. Drug Discovery
|September 5, 2002
Summary
Clinical proteomics applies protein analysis to cancer care, aiming for earlier detection, novel therapeutic targets, and personalized treatments. This field enhances understanding of protein networks in disease for improved patient outcomes.
Area of Science:
- Proteomics
- Clinical Proteomics
- Biomarker Discovery
Background:
- Proteomics aims to understand protein network information flow.
- This information is crucial in disease processes, including cancer.
- Clinical proteomics bridges proteomics research with patient care.
Purpose of the Study:
- To describe proteomic technologies for cancer research.
- To highlight applications in early cancer detection.
- To showcase advancements in biomarker discovery and tailored therapy.
Main Methods:
- Application of proteomic technologies in a clinical setting.
- Development of novel diagnostic and therapeutic strategies.
- Utilizing cancer as a model disease for proteomic applications.
Main Results:
- Proteomic technologies are advancing early cancer detection.
- New targets and imaging biomarkers are being discovered.
- Personalized cancer therapy approaches are being developed.
Conclusions:
- Clinical proteomics offers significant potential for improving cancer diagnosis and treatment.
- Proteomic advancements are key to personalized medicine in oncology.
- Cancer serves as a vital model for translating proteomic discoveries into clinical practice.